Autoimmune pulmonary alveolar proteinosis co-existing with breast cancer: a case report

Journal of Medical Case Reports

Shigeru Kohno¹  Naofumi Suyama²  Nobuko Matsuo²  Sumako Yoshioka²  Yasuhiro Umeyama²  Toyomitsu Sawai² 

[1] Second Department of Internal Medicine, Nagasaki University School of Medicine, 1-7-1 Sakamoto-machi, Nagasaki, Japan;Department of Respiratory Medicine, Nagasaki Harbor Medical Center City Hospital, 6-39 Shinchi-machi, Nagasaki 850-8555, Japan

关键词: Pulmonary alveolar proteinosis;    Co-existing;    Breast cancer;   

Others  :  1181073
DOI  :  10.1186/1752-1947-8-279

 received in 2014-04-17, accepted in 2014-07-03,  发布年份 2014

【 摘 要 】

Introduction

Pulmonary alveolar proteinosis is a rare pulmonary disease characterized by excessive alveolar accumulation of surfactant due to defective alveolar clearance by macrophages. There are only a few published case reports of pulmonary alveolar proteinosis occurring in association with solid cancers. To the best of our knowledge, there are no previously reported cases of pulmonary alveolar proteinosis associated with breast cancer.

Case presentation

A 48-year-old Asian woman, a nonsmoker, presented to our institution with a right breast mass. Biopsy examination of the lesion revealed scirrhous carcinoma. A chest computed tomography scan for metastases showed abnormal shadows in both upper lung fields. As a result of flexible fiberscopic bronchoscopy, this patient was diagnosed as having pulmonary alveolar proteinosis. This case was categorized as autoimmune pulmonary alveolar proteinosis due to the positive anti-granulocyte-macrophage colony-stimulating factor antibody. Pulmonary alveolar proteinosis decreased gradually after mastectomy.

Conclusions

The present case involved the coincident occurrence of autoimmune pulmonary alveolar proteinosis with breast cancer; breast cancer may be a factor during pulmonary alveolar proteinosis development.

【 授权许可】

   
2014 SAWAI et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 4.

【 参考文献 】

• [1]Rosen SH, Castleman B, Liebow AA: Pulmonary alveolar proteinosis. N Engl J Med 1958, 258:1123-1142.
• [2]Schiller V, Aberle DR, Aberle AM: Pulmonary alveolar proteinosis. Occurrence with metastatic melanoma to lung. Chest 1989, 95:466-467.
• [3]Garcia Rio F, Alvarez-Sala R, Caballero P, Prados C, Pino JM, Villamor J: Six cases of pulmonary alveolar proteinosis: presentation of unusual associations. Monaldi Arch Chest Dis 1995, 50:12-15.
• [4]Kadota J, Nakamura Y, Iwashita T, Ishimatsu Y, Matsubara Y, Yoshinaga M, Abe K, Oka M, Kohno S: Pulmonary alveolar proteinosis with lung squamous cell carcinoma. Respir Med 1999, 93:138-140.
• [5]Kim KH, Kim JH, Kim YW: Use of extracorporeal membrane oxygenation (ECMO) during whole lung lavage in pulmonary alveolar proteinosis associated with lung cancer. Eur J Cardiothorac Surg 2004, 26:1050-1051.
• [6]Cheewakriangkrai R, Litwin A, Nava ME, Ramnath N: Unusual thoracic problems in patients with long-standing pulmonary alveolar proteinosis. J Clin Oncol 2005, 23:2858-2859.
• [7]Su KC, Lay SL, Perng RP, Chang SC, Chen YM: Lung cancer may develop subsequently or coincidently with pulmonary alveolar proteinosis. Lung Cancer 2007, 58:144-148.
• [8]Liu H, Wang Y, He W, Xu Q: Lung squamous cell carcinoma in pulmonary alveolar proteinosis. Ann Thorac Cardiovasc Surg 2013, 8:1-4.
• [9]Sakagami T, Uchida K, Suzuki T, Carey BC, Wood RE, Wert SE, Whitsett JA, Trapnell BC: Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis. N Engl J Med 2009, 361:2679-2681.
• [10]Inoue Y, Trapnell BC, Tazawa R, Arai T, Takada T, Hizawa N, Kasahara Y, Tatsumi K, Hoji M, Ichikawa T, Tanaka N, Yamaguchi E, Eda R, Oishi K, Tsuchihashi Y, Kaneko C, Nukiwa T, Sakatani M, Krischer JP, Nakata K: Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med 2008, 177:752-762.
• [11]Borie R, Danel C, Debray MP, Taille C, Dombret MC, Aubier M, Epaud R, Crestani B: Pulmonary alveolar proteinosis. Eur Respir Rev 2011, 20:98-107.
• [12]Whitsett JA, Wert SE, Trapnell BC: Genetic disorders influencing lung formation and function at birth. Hum Mol Genet 2004, 13:207-215.
• [13]Athanassiadou PP, Athanassiades PH, Kostopoulos C, Kyrkou K, Petrakakou E, Veroni S: Antigen expression of alveolar macrophages in smokers and patients with lung diseases. Diagn Cytopathol 1995, 12:37-41.
• [14]Kitamura T, Uchida K, Tanaka N, Tsuchiya T, Watanabe J, Yamada Y, Hamaoka K, Seymour JF, Schoch OD, Doyle I, Inoue Y, Sakatani M, Kudoh S, Azuma A, Nukiwa T, Tomita T, Katagiri M, Fujita A, Kurashima A, Kanegasaki S, Nakata K: Serological diagnosis of idiopathic pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000, 162:658-662.
• [15]Seymour JF, Presneill JJ: Pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2002, 166:215-235.
• [16]Morgan H, Tumber A, Hill PA: Breast cancer cells induce osteoclast formation by stimulating host IL-11 production and downregulating granulocyte/macrophage colony-stimulating factor. Int J Cancer 2004, 109:653-660.
• [17]Liu XF, Xiang L, Zhang Y, Becker KG, Bera TK, Pastan I: CAPC negatively regulates NF-κB activation and suppresses tumor growth and metastasis. Oncogene 2012, 31:1673-1682.